Press Release: Squire Patton Boggs appoints new life sciences leader

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Press Release: Squire Patton Boggs appoints new life sciences leader

Sponsored by

Squire Patton Boggs

Squire Patton Boggs selects Janice Rice to lead the life and health sciences patent team

(PALO ALTO/SAN FRANCISCO – December 16, 2019) – Squire Patton Boggs is pleased to announce the appointment of partner Janice Rice to Deputy Practice Group Leader of the Intellectual Property & Technology Practice Group, leading the life and health sciences patent team. Ms. Rice will succeed Cameron Kerrigan, who founded the practice. Mr. Kerrigan will continue to be a partner in the practice group in the Palo Alto and San Francisco offices.

“Cameron has been dedicated to the founding and growth of the group for almost 20 years. Without him, we would not have a globally recognized life and health sciences patent practice. We thank him for his hard work and leadership,” said David S. Elkins, global chair of the Intellectual Property & Technology Practice Group. “And we are very confident that Janice will successfully continue Cameron’s hard work. She has excelled in her practice, business development and acumen, and has the skills necessary to excel as Deputy Practice Group Leader.”

Ms. Rice has been a patent lawyer for more than 16 years in the California community. For more than 12 years of that time, she served as in-house patent counsel at small to mid-sized pharmaceutical companies. Before law school, Ms. Rice worked for nine years as a synthetic organic chemist. Using her knowledge of chemistry and law, Ms. Rice’s practice includes developing US and international patent strategies, patent drafting and prosecution, evaluation and protection of trade secrets, patentability and freedom to operate analyses, patent due diligence and advising on intellectual property licensing issues.

“I am extremely proud of the strength of the Squire Patton Boggs life sciences group, and in particular, our unwavering focus on providing strategic business advice and on quality service to our clients. It is an honor to be part of such a strong team,” said Ms. Rice.

Moving forward in the role, Ms. Rice plans to continue to strengthen the business development practices of the group, bring her corporate experience to continue to build a strong team atmosphere for colleagues around the globe, and to continue the firm’s commitment to foster the growth of each individual and encouragement of women in particular, to take risks and follow their intuition.

 

ENDS

more from across site and SHARED ros bottom lb

More from across our site

Fresh off a string of ITC victories, Latham has recruited Baker Botts’ ITC leader Lisa Kattan, adding another prominent name to one of the market's busiest ITC practices
The firm hopes its recent Düsseldorf expansion and UK partner hire will strengthen its offering as it looks to an integrated model to boost UPC capabilities
Stephenson Harwood’s trademark prosecution push and patent ambitions could complement Taylor Wessing’s remaining but depleted European IP strength following its UK arm’s departure
Gerben IP’s first woman partner, Sophie Edbrooke, explains how boutique life allowed her to broaden her expertise, take on leadership responsibilities and carve out a route to the top
INTA has a right to protect its Annual Meeting, but making it harder for others to hold similar events risks leaving delegates with a bigger travel bill
The firm says it hopes to capture patent litigation work in Texas by arming itself with experienced trial lawyers with venue expertise
Ken Iijima's arrival continues a trend of ex-Pizzeys practitioners joining RnB IP, whose co-founder says independent ownership and a lucrative compensation model have become attractive in a consolidating market
McDermott Will & Schulte lawyers explore why the UPC is seeing rapid adoption by medtech for fast-moving disputes, while pharma and biotech take a cautious, selective approach over revocation risks
IP firms may be growing more comfortable with external capital, but uncertainty over who could ultimately own the business is complicating the investment pitch
The former Western District of Texas judge addresses perceptions of his courtroom, reveals what comes next as he returns to practice at A&O Shearman and explains why marathon running is ‘cathartic’
Gift this article